Related Experiment Video
Updated: Jun 14, 2026

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome
Published on: October 3, 2018
Patient selection for transplantation in the myelodysplastic syndromes
1Harvard Medical School, Dana-Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA. corey_cutler@dfci.harvard.edu
Abstract:
Allogeneic hematopoietic stem cell transplantation remains the only known curative procedure for the myelodysplastic syndromes (MDS). Because the median age at diagnosis for MDS is in the late seventh decade of life, despite the curative potential, transplantation is not undertaken routinely, and careful consideration must be made regarding the appropriateness of the transplant recipient. This article focuses on appropriate patient selection for transplantation for MDS.
Related Concept Videos
Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...
Kidney Transplant I: Introduction
Tissue Transplantation
The Biology of Tissue Transplantation
The biology of tissue transplantation hinges on the Major Histocompatibility Complex (MHC) molecules. These molecules...

